Total Payments
$77,763
2024 Payments
$49,038
Companies
32
Transactions
449
Medicare Patients
41,371
Medicare Billing
$5.4M
Payment Breakdown by Category
Other$59,880 (77.0%)
Food & Beverage$7,710 (9.9%)
Research$4,332 (5.6%)
Travel$4,153 (5.3%)
Consulting$1,688 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $59,880 | 37 | 77.0% |
| Food and Beverage | $7,710 | 401 | 9.9% |
| Unspecified | $4,332 | 2 | 5.6% |
| Travel and Lodging | $4,153 | 8 | 5.3% |
| Consulting Fee | $1,688 | 1 | 2.2% |
Payments by Type
General
$73,431
447 transactions
Research
$4,332
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $32,897 | 45 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21,993 | 28 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $19,900 | 249 | $0 (2024) |
| Kiniksa Pharmaceuticals International, plc | $480.60 | 27 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $329.16 | 16 | $0 (2024) |
| Eli Lilly and Company | $187.21 | 1 | $0 (2024) |
| CeloNova BioSciences, Inc. | $175.68 | 1 | $0 (2019) |
| PFIZER INC. | $175.18 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $157.89 | 9 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $138.23 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49,038 | 131 | Lilly USA, LLC ($29,647) |
| 2023 | $11,644 | 73 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,046) |
| 2022 | $15,306 | 76 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,839) |
| 2021 | $290.36 | 27 | Novartis Pharmaceuticals Corporation ($190.70) |
| 2020 | $23.61 | 2 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($12.52) |
| 2019 | $653.86 | 48 | Novartis Pharmaceuticals Corporation ($249.61) |
| 2018 | $538.58 | 57 | Novartis Pharmaceuticals Corporation ($350.66) |
| 2017 | $268.33 | 35 | Novartis Pharmaceuticals Corporation ($156.45) |
All Payment Transactions
449 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Abbott Laboratories | MITRACLIP (Device) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: Vascular | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| 12/11/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/09/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: Obesity | ||||||
| 12/09/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,450.00 | General |
| Category: Obesity | ||||||
| 12/05/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/04/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $743.45 | General |
| 12/04/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Obesity | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/20/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $30.78 | General |
| Category: Not Applicable | ||||||
| 11/19/2024 | Eli Lilly and Company | — | — | In-kind items and services | $187.21 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 11/15/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: Obesity | ||||||
| 11/15/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $875.00 | General |
| Category: Obesity | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $7.14 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/12/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: Obesity | ||||||
| 11/12/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,450.00 | General |
| Category: Obesity | ||||||
| 11/12/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $575.00 | General |
| Category: Obesity | ||||||
| 11/12/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $38.80 | General |
| Category: Not Applicable | ||||||
| 11/12/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $37.97 | General |
| Category: Obesity | ||||||
| 11/07/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $660.51 | General |
| 11/07/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $77.34 | General |
| Category: Obesity | ||||||
| 11/06/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $2.58 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/21/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $29.62 | General |
| Category: Not Applicable | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Review Article | Novartis Pharmaceuticals Corporation | $4,145 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $187.21 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 67 | 10,235 | 69,870 | $3.6M | $1.6M |
| 2022 | 64 | 10,132 | 41,841 | $3.7M | $1.6M |
| 2021 | 64 | 10,285 | 27,906 | $2.9M | $1.1M |
| 2020 | 61 | 10,719 | 24,473 | $2.7M | $1.0M |
Total Patients
41,371
Total Services
164,090
Medicare Billing
$5.4M
Procedure Codes
268
All Medicare Procedures & Services
268 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 88 | 43,736 | $524,832 | $409,301 | 78.0% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Office | 2023 | 214 | 215 | $688,000 | $265,524 | 38.6% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 226 | 442 | $257,100 | $179,295 | 69.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,300 | 1,955 | $488,750 | $164,115 | 33.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 193 | 193 | $164,730 | $64,036 | 38.9% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 88 | 90 | $135,000 | $56,631 | 41.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 397 | 400 | $152,740 | $54,581 | 35.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 297 | 1,196 | $135,148 | $51,093 | 37.8% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 194 | 387 | $58,050 | $36,065 | 62.1% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 116 | 544 | $59,840 | $23,696 | 39.6% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 451 | 468 | $65,520 | $22,178 | 33.8% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Office | 2023 | 213 | 217 | $55,582 | $21,924 | 39.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,444 | 2,132 | $63,960 | $21,085 | 33.0% |
| 78433 | Nuclear medicine study of heart muscle with metabolic and blood flow evaluation requiring 2 injections and concurrent ct scan | Office | 2023 | 12 | 12 | $48,000 | $17,900 | 37.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 135 | 136 | $46,330 | $17,876 | 38.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 119 | 128 | $44,800 | $15,451 | 34.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 139 | 139 | $41,700 | $15,448 | 37.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 268 | 270 | $48,600 | $15,399 | 31.7% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Office | 2023 | 70 | 70 | $45,640 | $14,453 | 31.7% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 91 | 462 | $36,960 | $13,527 | 36.6% |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 95 | 387 | $34,830 | $13,163 | 37.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 133 | 217 | $32,410 | $13,029 | 40.2% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Office | 2023 | 133 | 136 | $31,135 | $11,681 | 37.5% |
| 83880 | Natriuretic peptide (heart and blood vessel protein) level | Office | 2023 | 222 | 295 | $23,600 | $11,300 | 47.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 96 | 300 | $27,000 | $10,885 | 40.3% |
About Dr. Lance Sullenberger, MD
Dr. Lance Sullenberger, MD is a Cardiovascular Disease healthcare provider based in Albany, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174623086.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lance Sullenberger, MD has received a total of $77,763 in payments from pharmaceutical and medical device companies, with $49,038 received in 2024. These payments were reported across 449 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($59,880).
As a Medicare-enrolled provider, Sullenberger has provided services to 41,371 Medicare beneficiaries, totaling 164,090 services with total Medicare billing of $5.4M. Data is available for 4 years (2020–2023), covering 268 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Albany, NY
- Active Since 09/22/2006
- Last Updated 01/30/2015
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1174623086
Products in Payments
- ZEPBOUND (Drug) $26,825
- JARDIANCE (Drug) $26,000
- LEQVIO (Drug) $16,933
- ENTRESTO (Drug) $1,280
- Arcalyst (Drug) $480.60
- CAMZYOS (Drug) $266.27
- VYNDAQEL (Drug) $175.18
- VERQUVO (Drug) $157.89
- XARELTO (Drug) $138.23
- AMVUTTRA (Drug) $122.88
- Sotalol Hydrochloride (Drug) $121.50
- MITRACLIP (Device) $100.05
- Cleerly Ischemia (Device) $90.58
- LifeVest (Device) $87.51
- BYSTOLIC (Drug) $66.77
- FARXIGA (Drug) $63.75
- ELIQUIS (Drug) $62.89
- Inpefa (Drug) $53.15
- MoMe Kardia (Device) $48.68
- Venclose Maven Catheter (Device) $45.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Albany
Augustin Delago, Md, MD
Cardiovascular Disease — Payments: $1.7M
Cardiovascular Disease $1.7M
Dr. Edward Philbin, M.d, M.D
Cardiovascular Disease — Payments: $168,225
Cardiovascular Disease $168,225
Brion Winston, Md, MD
Cardiovascular Disease — Payments: $93,572
Cardiovascular Disease $93,572
Akshay Kamath
Cardiovascular Disease — Payments: $70,431
Cardiovascular Disease $70,431
Dr. Michael Martinelli, M.d, M.D
Cardiovascular Disease — Payments: $64,261
Cardiovascular Disease $64,261
Dr. Colin Hirst, Md, MD
Cardiovascular Disease — Payments: $63,897
Cardiovascular Disease $63,897